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Most deaths from solid cancers occur as a result of secondary metastasis to distant sites. Bone is the most
frequent metastatic site for many cancer types and can account for up to 80% of cancer-related deaths in
certain tumours. The progression from a discrete solid primary tumour to devastating and painful bone
metastases is a complex process involving multiple cell types and steps. There is increasing evidence that
modulation of the extracellular matrix plays an important role in the lethal transition from a primary to
disseminated metastatic bone tumour. This review provides an overview of the current understanding on
the role of role of lysyl oxidase, the extracellular matrix and the pre-metastatic niche in bone metastasis
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Once a primary tumour spreads to distant sites in the body and
establishes a secondary tumour, the consequences are devastating,
and mostly lethal. Bone is a typical site for cancers to spread to (most
commonly breast, prostate, lung, kidney, thyroid and colon cancer) –
however why cancer cells preferentially home to bone over other or-
gans in some cancers, but not all, is not fully understood. There is
increasing evidence that modulation of the extracellular matrix (ECM)
plays an important role in the lethal progression from a primary to
metastatic bone tumour. Yet it is not known which occurs ﬁrst, ab-
normal extracellular matrix (ECM), which supports secondary tumour
formation, or the arrival of cancer cells into the bone that create ab-
normal ECM. Recently it has been shown that tumour-derived factors
circulate the body and exert effects on ECM remodelling within distant
organs, creating so-called pre-metastatic niches. This review provides
an overview of the current understanding on the role tumour secreted
lysyl oxidase (LOX) and modulation of the ECM in bone metastasis.2. ECM determines cell behaviour
The extracellular matrix (ECM) is made up of over 300 proteins, the
majority of which are ﬁbrous proteins (e.g. ﬁbronectin, elastin and
collagens) and proteogylcans (e.g. keratin sulphate, heparin sulphate,GmbH. This is an open access art
isk Foundation Hallas Møller
).chondroitin sulphate). Typically, these proteins are secreted locally and
assemble into a complex network of macromolecules, or an “organised
mesh”, which has distinctive physical, biochemical and biomechanical
properties and which forms the structural framework of most tissues.
Previously perceived as being a stable scaffold with merely a suppor-
tive role in maintaining tissue morphology, the ECM has now emerged
as a dynamic entity and a critical regulator of cell physiology. The
versatile nature of the ECM components means that this organised
mesh has very unique properties that, through direct or indirect
means, regulates almost all cellular behaviour and when tightly con-
trolled is fundamental for embryonic development and organ home-
ostasis. For example the physical properties of the ECM (rigidity, por-
osity, topography etc) dictate the tissues architecture and integrity,
whilst acting as an anchorage site as well as a migration track or
barrier, having both positive and negative inﬂuences on cell migration.
The biochemical properties of the ECM confer cells with the capability
to “sense” and interact with their environment either in a direct (by
acting as precursor of biologically active signalling fragments) or in-
direct (by binding growth factors and limiting their diffusive range)
manner that results in signal transduction cascades, gene expression
or other changes in cellular behaviour. Finally, the biomechanical
properties of the ECM also dictates cellular behaviour due to its huge
range in elasticity (from soft and compliant to stiff and rigid) enabling
the cell to sense external forces. Thus, the ECM acts as mechan-
otransducer that translates mechanical tissue loading into cellular
signals determining cell behaviour; a process that is particularly critical
in the lifelong maintenance of healthy bone.
Given the importance of the ECM in directing almost all cellular
behaviour, it is not too surprising that altered ECM deposition,
synthesis and post-translational modiﬁcation leads to a dis-
organised mesh with differing properties and results in diseasesicle under the CC BY-NC-ND license
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how increased stiffness translate into regulation of cellular pro-
cesses such as motility, proliferation and survival please see Cox
and Erler 2014 [1] and Pickup et al. 2015 [2]).3. ECM, cancer and metastasis
For cells to become cancerous they must acquire the ability to
survive, grow and invade leading to malignant transformation,
tumour formation and ultimately overt secondary metastasis.
Abnormal ECM can promote these abilities and is a well-docu-
mented hallmark of cancer. In fact, it has also been shown that
aberrant ECM can precede malignant transformation in many tis-
sues [3]. In addition, many ECM components and their receptors
are overexpressed by cancer cells which typically leads to abnor-
mal ECM that may potentiate the oncogenic effect of various
growth factors, including ones known to be fundamental in bone
remodelling, such as VEGF, IGF-1 and TGF-??. Whether these
events occur concomitantly or one proceeds the other is much like
asking which came ﬁrst came ﬁrst the chicken (ECM) or the egg
(cancer)! It would be interesting to gain further insight into the
nature and indeed timing of these changes, as well as under-
standing similarities and differences in the changes within the
ECM and the cancer cells themselves.
Physiological changes in the external environment of the tu-
mour, such as hypoxia can also lead to changes in the ECM due to
increased expression of enzymes responsible for the post-trans-
lational modiﬁcation of collagen and other ECM components. This
includes the lysyl oxidase (LOX) family of extracellular amine
oxidases whose primary function is to post-translationally modify
collagens and elastin in the ECM, thereby catalysing the covalent
crosslinking of collagen ﬁbres increasing stiffness and tensile
strength. The increased stiffness of the ECM is “sensed” by the
cancer cells which in turn focus their activities towards invasion,
as opposed to proliferation, and drives them to migrate to distant
metastatic sites. Consistent with this, the LOX enzyme was shown
to be associated with lower distant metastasis-free survival and
overall survival in breast cancer patients with ER-negative tu-
mours, and also in head and neck cancer patients [5]. Expression
of another LOX family member, LOX Like protein-2 (LOXL-2) was
similarly shown to be correlated with metastasis and decreased
survival in patients with aggressive breast cancer. Although not
required for primary tumour growth, LOXL-2 was required for
metastatic colonisation and metastatic growth in vivo. Mechan-
istically, LOXL-2 was shown to regulate the expression and activity
of other ECM modifying proteins including tissue inhibitor of
metalloproteinase-1 (TIMP1) and matrix metalloproteinase-9
(MMP9), key proteins involved in ECM remodelling [6]. Targeting
of LOXL-2 with an inhibitory monoclonal antibody (AB0023) was
also shown to be efﬁcacious in both primary and metastatic xe-
nograft models of cancer [7]. Further evidence that the LOX pro-
teins can induce changes in the tumours ECM's physical properties
to facilitate metastasis was provided more recently with the ob-
servation that LOX-mediated collagen crosslinking creates a
growth-permissive ﬁbrotic microenvironment capable of sup-
porting metastatic growth by enhancing tumour cell persistence
and survival [8]. Strikingly, not only do LOX enzymes modulate the
ECM of the primary tumour, but they can also modulate the ECM
of distant organs to form the pre-metastatic “niche” prior to the
arrival of tumour cells and development of metastases [9]. The
exact mechanisms behind this niche formation are not known; do
tumour-derived factors circulate the body and exert differing ef-
fects on ECM remodelling within different organs, or do particular
tumour-secreted factors initiate speciﬁc cascade reactions and
signalling events in speciﬁc tissues? Pertinent to this review, theability of these enzymes to modulate the ECM in the bone to fa-
cilitate bone metastasis is only now just being recognised [10].4. ECM and bone metastasis
When considering the constituents of the ECM, as well as the
molecular pathways involved in the dysregulation of the ECM that
leads to oncogenic transformation, the similarity and overlap with
the constituents of bone and the pathways involved in its home-
ostasis and remodelling are obvious. Bone is the largest “organised
mesh” (by mass) in the human body – providing the ultimate
scaffold that dictates the human form and ultimately function.
Bone, like any other ECM, consists of ﬁbrous proteins, pre-
dominantly type I collagen, and non-collagenous proteins such as
proteoglycans, and glycoproteins such as osteopontin and ﬁ-
bronectin. The fact that many cancers have a predilection to me-
tastasise to bone should perhaps not be so surprising then. How-
ever, unlike other ECMs bone is physiologically mineralized (thus
100,000–1,000,000 times stiffer than other tissues such as breast
tissue). Bone is constantly remodelled throughout life, continually
synthesizing osteoid – the unmineralised collagenous matrix
which makes up about 50% of the bone's volume. These two
properties should in theory preclude and facilitate invasion of
cancer cells in the bone respectively, yet this appears not to be so.
Stephen Paget ﬁrst proposed the “seed and soil” hypothesis back in
1889 [11], this seminal paper and the resultant century or more of
research has led to concept of the “bone and cancer vicious cycle”
whereby once cancer cells arrive in the bone they release factors
that stimulate osteoclastic bone resorption (IL-6, IL-8, MMPs
TIMPS etc). This bone resorption causes the release of bone stored
factors (in particular TGF-β) that favour the growth of the tumour
in bone, which inevitably stimulates more osteoclastic bone de-
struction, and so on. Signiﬁcant advances in identifying key play-
ers in the vicious cycle have been made in the last decade, with
many attempts to prevent bone metastasis being focused on tar-
geting this vicious cycle.
But the big question on most bone oncologists lips, and which
remains largely unanswered, is why do certain circulating tumours
cells particularly home to bone in the ﬁrst place? Whilst there are
many theories from hijacking stem cell niches to osteomimicry,
there is one in particular that is at the same time an intriguing and
horrifying concept – that is the ability of the primary tumour to
modify the bone's ECM to facilitate the initiation of the vicious
cycle of bone metastasis prior to the arrival of tumour cells.
In an effort to determine whether the primary tumour might be
responsible for “fertilising” the bone “soil” ready for the cancer
“seed”, we recently found that a hypoxic gene signature, and more
speciﬁcally the secreted enzyme lysyl oxidase (LOX) was closely
associated with bone metastasis, speciﬁcally in estrogen receptor
negative (ER-) breast cancer patients. We further investigated the
role of LOX in bone metastasis in vivo and found that tumour-
bearing mice showed increased bone loss and the formation of
focal osteolytic lesions over time. Whilst this would not be too
surprising an observation in a mouse that has overt bone metas-
tases – we found these changes occurred from as little as 2-weeks
post tumour implantation (when no metastases are present) and
that they could be recapitulated by injection of cell-free condi-
tioned medium (secreted factors) from cancer cells into mice.
These changes were LOX-dependent, as cancer cells expressing
shLOX injected into mice showed signiﬁcantly less osteolytic le-
sions. Our data clearly showed that early osteolytic lesions are
formed in the absence of tumour cells by hypoxia-induced tu-
mour-secreted factors. Mechanistically these macroscopic changes,
which would directly alter the physical, biochemical and bio-
mechanical properties of bone ECM, were as a result of LOX
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favour of bone degradation and the formation of pre-metastatic
osteolytic lesions. The physiological consequence of these ECM
changes were increased metastatic burden in the bone, with mi-
cro-CT analysis revealing a positive correlation between lesion
number and tumour burden. This demonstrated that LOX-medi-
ated pre-metastatic changes to bone ECM led to the generation of
pre-metastatic niches within the bone microenvironment that
support colonisation of circulating tumour cells and the formation
of overt bone metastases [13]. Furthermore, LOX may well be a
useful marker for predicting the likelihood of metastases to the
bone in ER- breast cancer patients and identifying these patients
for early adjuvant bisphosphonate treatment. Similarly, in the fu-
ture anti-LOX therapy, may prevent secondary bone cancer form
occurring. Interestingly, a recent meta-analysis from the Early
Breast Cancer Trialists’ Collaborative Group recently conﬁrmed
that adjuvant bisphosphonates reduce the rate of breast cancer
recurrence in the bone and improve breast cancer survival, albeit
with deﬁnite beneﬁt only in women who were postmenopausal
when treatment began [14]. For more information on this see our
recently published Cancer Research Review [15].
Increasing evidence for the role of the LOX family of proteins in
other cancers that metastasise to bone, speciﬁcally prostate cancer,
has recently been provided. Caley and colleagues demonstrated
that the tumour-associated collagen receptor Endo180 and the
crosslinking of collagen by stromal-derived LOX controls tumour
cell movement and as such is a potential target for limiting me-
tastatic progression in prostate cancer [16]. In another study by
Alsulaiman and colleagues whose initial aim was to provide evi-
dence to support previous work that suggests LOX pro-peptide
(LOX-PP), an 18KDa pro-peptide that is formed as Pro-LOX is
processed by procollagen C-proteinases to yield the mature LOX
enzyme, acts as a tumour suppressor. However, unexpectedly they
found that LOX-PP was able to stimulate osteoblast differentiation
as well as osteoclast formation and differentiation either in the
presence or absence of exogenously added RANKL and M-SCF.
Intramedullary injections of PC3 cells expressing LOX-PP showed
increased osteoclast resorption and bone destruction in vivo,
whilst the effect to enhance the development of osteoblastic le-
sions in the DU145 cells expressing LOX-PP was absent in their
model [17]. This apparent paradox, that the effects of LOX-PP in all
soft tissue tumour studies so far have demonstrated a beneﬁcial
outcome, whilst in mineralized tissue, LOX-PP shifts the balance
towards a destructive, pro-cancerous effect could be due to the
very unique properties of bone ECM. Delineating the differences
between the effects of the same protein on different ECM will have
beneﬁcial therapeutic value for both types of cancer.
Other proteins reported to play a role in bone marrow altera-
tion and bone metastasis include (but not limited to) CXCR4, IL-11,
IL-6, IL-8, TGF-βs, BMPs, CTGF, various MMPs and PTHrP. However,
most of these have been shown to be important once the tumour
cells arrive in the metastatic site and not before. Determining
whether these molecules also play a role in pre-metastatic niche
formation warrants further investigation.5. Future perspectives
Identiﬁcation of LOX as a modulator of the ECM to form pre-
metastatic niches and subsequently bone metastasis arose as we
were investigating the hypoxia tumour secretome using existing
patient cohort data and cutting edge proteomics. Although con-
doned by some researchers as “ﬁshing” experiments, the “hy-
pothesis-free” comparative or subtractive analysis approach has
proved to catch some important targets. At the start of the 21st
century use of gene microarrays enabled the interrogation ofbetween 15,00025,000 genes at a time and led to the identiﬁ-
cation of regulators of breast cancer to bone metastasis such as
interleukin-11 and CTGF [18] as well as ECM genes such as POEM
[19]. In just over a decade, technology has improved our capacity
to comprehensively proﬁle genes as wells as secreted proteins
associated with bone metastasis. This has led to the identiﬁcation
of novel biomarkers and candidate therapeutic targets such as LOX
family members [13,15,20,21], cystatins (CST1, CST2, and CST4),
plasminogen activators (PLAT and PLAU) and collagen functionality
proteins (PLOD2 and COL6A1) [20].
The ethos of publically sharing data sets [21], the increasing
availability (and reduction in cost) of deep-read RNA sequencing
and whole genome sequencing methodology, plus the progress in
systems biology/bioinformatics in the last 5 years or so will mean
that these sophisticated ﬁshing expeditions are bound to net a
considerable haul of potential therapeutic targets.
In summary, in an effort to contain tumours to their primary
site, and thereby limit the high morbidity and mortality associated
with metastasis, the targeting of tumour secreted molecules and
prevention of pre-metastatic niche formation offers a powerful
therapeutic option. (Fig. 1).
At the site of a primary tumour, cells become cancerous and
acquire the ability to survive, grow and invade leading to malig-
nant transformation, tumour formation and ultimately overt sec-
ondary metastasis. (1) Abnormal ECM can promote normal cells to
become cancerous (blue arrows). In addition as cells undergo
oncogenic transformation, many ECM components and their re-
ceptors are overexpressed by cancer cells which typically leads to
abnormal ECM (red arrows). Whether these events occur con-
comitantly or one proceeds the other is much like asking which
came ﬁrst came ﬁrst the chicken (ECM) or the egg (cancer)! Once a
primary tumour has established circulating tumour cells will
eventually arrive in distant sites such as bone (osteotropism).
(2) Once a tumour cell is present in the bone a “vicious cycle”
occurs whereby cancer cells release factors which enhances the
osteoblastic stimulation of osteoclast resorption. This resorption of
bone changes the bone ECM, releasing stored growth factors
which promote cancer cell growth, and so on. 2A More recently it
has been shown that primary tumour cells release proteins and
ECM components which modulate the bone ECM prior to the ar-
rival of cancer cells and initiation of the vicious cycle. (3) Once the
changes in the distant metastatic site have taken place cancer cell
recruitment takes place and the result is overt metastasis (with or
without involvement of the vicious cycle), which in the case of
secondary bone cancer has lethal consequences.The main outstanding questions Why do certain cancer cell types preferentially home to bone?
 Speciﬁcally what is it about mineralized tissue that makes it
such a favourable place to grow?
 Which occurs ﬁrst - abnormal extracellular matrix (ECM) which
drives oncogenic transformation, or cancerous cells which cre-
ate abnormal ECM?
 Does bone remodelling need to, at least in part, occur before
cancer cells can successfully colonise? Or, do cancer cells start
the remodelling only when they arrive in the bone marrow. Or
both?
 Do tumour-derived factors circulate the body and exert differing
effects on ECM remodelling within different organs, or do par-
ticular tumour-secreted factors initiate speciﬁc cascade reac-
tions and or other signalling in speciﬁc tissues?
 Are there any built-in mechanisms within the bone which may
restrict, or accelerate aberrant ECM remodelling?
Fig. 1. ECM changes in bone metastasis.
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